Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-02-04
1995-03-21
Springer, David B.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
546175, C07D25704, C07D40312, A61K 3141, A61K 3147
Patent
active
053997034
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to a tetrazole derivative of the following general formula [I] or a pharmacologically acceptable salt thereof. ##STR2## wherein A means --(O)m--(CH(R.sup.4))n-- (R.sup.4 is hydrogen or alkyl; m and n each is 0 or 1); B means oxygen or --S(O)p-- (p is 0 to 2) ; R.sup.1 means hydrogen, lower alkyl, lower alkoxy, halogen, haloalkyl or hydroxy; R.sup.2 means alkyl, alkenyl or aralkyl, which may be substituted or unsubstituted; R.sup.8 means hydrogen, lower alkoxy or halogen; R.sup.9 means hydrogen, lower alkyl, lower alkoxy, lower acyloxy, halogen, nitro or hydroxy; R.sup.10 means hydrogen or lower alkyl.
The compound according to the invention has antiallergy and antiinflammatory activities and is of use for alleviation and relief of allergic symptoms such as bronchial asthma, urticaria, allergic rhinitis and atopic dermatitis or as a therapeutic agent for cardiovascular disorder, cerebrovascular disorder, inflammation, arthritis and other diseases.
BACKGROUND ART
It is generally believed that allergic asthma and atopic diseases are induced as a variety of chemical mediators are released from the lung and other tissues to contract smooth muscles such as the bronchial muscle and pulmonary blood vessels or increase the permeability of blood vessels of the skin to thereby inflict various damages on various tissues.
Of such chemical mediators, histamine and SRS-A have been considered to be of the greatest significance. Recently, SRS-A was identified to be a mixture of leukotrienes LTC.sub.4, LTD.sub.4 and LTE.sub.4, which are peptides, and the multi-pronged physiological action of these leukotrienes (LT) and their association with various pathologic states have been extensively explored. By origin, SRS-A is a lipoxygenase-catalyzed metabolite of arachidonic acid and much interest has been focused on the role it plays as a substance involved in the onset or progression to refractoriness of bronchial asthma and other diseases arising from immediate type allergic reactions.
In fact, LTC.sub.4 and LTD.sub.4 strongly contract the isolated guinea pig and human tracheas and enhance the secretion of mucus from the human respiratory tract in vitro. Therefore, particular attention has been paid to their involvement in bronchial asthma.
Clinically, too, LT has been demonstrated in the sputum of patients with, for example, bronchitis in concentrations sufficient to produce physiological changes. It has also been reported that, in children with bronchial asthma, the blood LTC.sub.4 level is well correlated with the severity of the disease.
Asthma being set aside, it has been suggested that LT is associated with allergic rhinitis and dermatitis and even with ischemic diseases such as myocardial infraction etc., cardiac anaphylaxis, endotoxin shock, psoriasis and so forth.
Therefore, there is a mounting interest in the development of drugs which would either inhibit the production of SRS-A or antagonize SRS-A.
Thus, for example, FPL-55712, SKF-104353, WY-45911 and ONO-1078, among others, are known as LT antagonists. However, none have been commercially available as yet. [Tohn H. Musser et al., New development concerning Leukotriene Antagonists. Agents and Actions, 18 (3/4) 332 (1986), Drugs of the Future, 13(4) 317 (1988)].
Japanese Kokai Tokkyo Koho 62-198652 describes a group of compounds not alien to the compound of this invention, with the comment that some of the compounds have 5.alpha.-reductase inhibitory activity. The description in the claim of the corresponding specification might suggest that the compound of the present invention is subsumed therein but nowhere in the same specification is found a specific disclosure of any compound having a tetrazoyl group. Furthermore, there is no statement suggestive of the pharmacologic actions characteristic of the compound of the present invention. Incidentally, it has been proven that the compound of the present invention has no 5.alpha.-reductase activity at all.
DISCLOSURE OF INVENTION
The inventors of the present invention have done much
REFERENCES:
patent: 4372953 (1983-02-01), Uchida et al.
patent: 4661505 (1987-04-01), Marshall et al.
Inoue Kichiro
Makita Yoshihiko
Nakanouchi Kei
Yasufuku Shoji
Yoshimoto Yoshihiko
Nippon Shinyaku Company Limited
Springer David B.
LandOfFree
Tetrazole derivatives and drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrazole derivatives and drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrazole derivatives and drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1149979